Vice President Kamala Harris delivered a closing argument speech at the Ellipse, the site of former President Trump’s Jan. 6, 2021, rally. She drew a contrast between her vision for the country and ...

It’s hard to ignore the seismic shifts brought about by algorithm-driven content. Every time you scroll through your social media feed or check your favorite news app, algorithms are diligently at ...

“Algospeak” capitalizes on our desire for attention and status. We should turn to God for both. I’ll typically start formulating ideas around 7 a.m. Thanks to a steady stream of information from my ...

New Balance running shoes have been a staple in my sneaker rotation for years — I have 11 pairs in my closet right now — but given the brand’s tendency to release new iterations of its existing styles ...

This is read by an automated voice. Please report any issues or inconsistencies here. See more from the L.A. Times in Google Search. Set us as preferred We are more connected than ever before, with ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

It seems like the buzziest running shoes launches of late put an emphasis on pace, performance and carbon plates. However, the latest shoe in the New Balance running portfolio, the Ellipse, takes a ...

The workplace can be a tricky place to navigate. Almost everything we do at work—identifying the experts, managing tough feedback from a boss, figuring out how to work in teams made up of different ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...